Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice

• Published in: Bulletin of experimental biology and medicine 2019-06, Vol.167 (2), p.210-214
• Main Authors: Michurina, S. V., Cherepanova, M. A., Ishchenko, I. Yu, Arkhipov, S. A., Klimontov, V. V., Zav’yalov, E. L.
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Apoptosis - drug effects; Bcl-2 protein; bcl-Associated Death Protein - metabolism; Biomedical and Life Sciences; Biomedicine; Cell Biology; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Dipeptidyl-peptidase IV; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Fatty liver; Hepatocytes; Internal Medicine; Laboratory Medicine; Linagliptin; Linagliptin - therapeutic use; Liver; Liver diseases; Male; Mice; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Obesity; Obesity - drug therapy; Obesity - metabolism; Pathology; Peptidase; Proteins; Proto-Oncogene Proteins c-bcl-2 - metabolism; Rodents; Type 2 diabetes
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-019-04493-1

We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin on the expression of apoptosis regulator proteins Bcl-2 and Bad in the liver of db / db mice with genetically determined obesity and type 2 diabetes mellitus. The mice received daily linagliptin or saline (placebo) by gavage from week 10 to week 18 of life. In the liver of non-treated mice, the area positively stained for Bad was greater than the area of Bcl-2 expression, which created the conditions for apoptosis activation in liver at this age. Administration of linagliptin decreased Bad stained area and increased Bcl-2 stained area in the liver cells. At the same time, Bad stained area remained larger in treated mice than the area of Bcl-2 expression area, which attested to partial normalization of pro- and antiapoptotic protein balance.